No Data
Express News | Overview of A-shares Share Buyback: 36 companies disclosed their buyback progress.
Chengdu Kanghua Biological Products (300841.SZ): The phase III clinical trial approval notice for the six-valent Norovirus vaccine (Pichia pastoris) has been obtained.
Chengdu Kanghua Biological Products (300841.SZ) announced that recently, the company developed a recombinant hexavalent norovirus vaccine (Pichia pastoris...
Chengdu Kanghua Biological Products (300841.SZ): Currently, the AI Siasun Robot&Automation Business has not been developed.
Glory Network reported on December 11 that Chengdu Kanghua Biological Products (300841.SZ) stated on the investor interaction platform that the company mainly engages in the research, production, and sales of human vaccines and has not yet started its Business in Siasun Robot&Automation.
Express News | Chengdu Kanghua Biological Products: Shareholders holding more than 5% and other shareholders plan to reduce their shareholding in the company.
chengdu kanghua biological products (300841.SZ): The construction of the raw liquid workshop for ACYW135 meningococcal polysaccharide vaccine group has been completed.
On November 6, Gelunhui reported that Chengdu Kanghua Biological Products (300841.SZ) stated on the investor interaction platform that the company has completed the construction of the ACYW135 group meningococcal polysaccharide vaccine raw liquid workshop and the "Chengdu Kanghua Biological Products Vaccine Production Expansion Project", which are currently in the supplementary application stage for pharmaceutical production permits, and can be put into production after obtaining the production permit.
Kanghua Biology: Report for the third quarter of 2024
